Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 2Leukemia 2Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Cerebral Palsy 1

Interventions

ofatumumab 3Vincristine 2Rituximab 2Lenalidomide 2Bortezomib 2tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1nelarabine 1immunotoxin HA22 1fludarabine 1bempegaldesleukin 1Whole-Body Irradiation 1Tablets 1Panobinostat 1Observation 1Nivolumab 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Everolimus 1Etoposide 1Drug Therapy 1Dexamethasone 1DTRMWXHS-12 1Cytarabine 1Cyclophosphamide 1Clofarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, B-Cell × immunotoxin HA22 × Clear all
NCT02227108 2017-04-06

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

MedImmune LLC

Phase 2 Terminated
37 enrolled 24 charts
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡